Jefferies Downgrades Mirati Therapeutics to Hold, Raises Price Target to $58
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Maury Raycroft has downgraded Mirati Therapeutics (NASDAQ:MRTX) from Buy to Hold, while raising the price target from $55 to $58.
October 09, 2023 | 9:05 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mirati Therapeutics has been downgraded from Buy to Hold by Jefferies, although the price target has been raised from $55 to $58.
The downgrade from Buy to Hold suggests that Jefferies sees limited upside potential for MRTX in the short term. However, the raised price target indicates that they still see some value in the stock. This could lead to a neutral impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100